A carregar...
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
BACKGROUND: Two randomized controlled trials (reSURFACE 1 and 2) have demonstrated the effectiveness of tildrakizumab, a high‐affinity, humanized, IgG1κ, anti‐interleukin‐23 monoclonal antibody, for treating moderate‐to‐severe plaque psoriasis in the first 28 weeks. OBJECTIVES: To examine the effica...
Na minha lista:
| Publicado no: | J Eur Acad Dermatol Venereol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899626/ https://ncbi.nlm.nih.gov/pubmed/31407394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15862 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|